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Abstract
Nowadays, nanomaterials have rapidly developed as a new generation of antibacterial agents. However, high local aggrega-
tion and concentration, and possible toxicity due to excess leaching are disadvantages of nanoparticles. Unique features of 
metal–organic frameworks (MOFs) such as coordinately unsaturated centers, high surface area and facile synthesis attracted 
attention to overcome the above-mentioned problems. In this context, Ag/MIL-101(Cr)/IMI was synthesized, and after 
characterization by powder X-ray diffraction (XRD), field emission scanning electron microscopy (FE-SEM–EDX), Trans-
mission Electron Microscopy (TEM), Fourier-transform infrared spectroscopy (FTIR), inductively coupled plasma-optical 
emission spectrometry and BET surface area, TG–DTA was used as an antibacterial agent. Imidazole-functionalized Ag/
MIL-101(Cr)/IMI presented a synergistic effect of imidazole and silver NPs against Escherichia coli (ATCC25292) and 
Staphylococcus aureus (ATCC25293) bacteria. The best antibacterial activity as minimum inhibitory concentration (MIC) 
was 6.2 µg/mL and 24.78 µg/mL of silver content against E. coli and S. aureus, respectively. There were 81 and 144.9 mg 
of Ag and imidazole per each gram of Ag/MIL-101(Cr)/IMI, which leaching rates of Ag, imidazole and Cr were 150, 828 
and 153 µg/L, respectively. This leaching level of imidazole was lower than the amount recommended by Registry of Toxic 
Effects of Chemical Substances (RTECS) from NIOSH, while the leaching levels of silver NP and chromium is tended to 
be around the standard of WHO and U.S.EPA.
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1 Introduction
Microbial contamination is one of the most problems in 
hospitals, medical equipment, and health care systems [1], 
food packaging and storage [2], textiles [3], water filtra-
tion equipment [4] and indoor air control systems [5, 6]. 
Nowadays, infection by microorganisms is becoming a seri-
ous and compelling subject for people’s health. Infections 
threaten human life, while high costs impose on societies [1, 
7]. However, preparation of a new antimicrobial agent by the 
potential biofunctional antibacterial strategy is essential to 
produce the biocidal materials [8, 9].
Metals such as Ag, Zn, and Cu and metal oxides such 
as ZnO,  Cu2O and CuO nanoparticles are very well known 
compounds as antibacterial agents [10, 11]. Silver NP is one 
of the best metals with high antibacterial efficiency in the 
sizes less than 30 nm and less toxicity than many other nano-
materials [10, 12–14]. But the use of silver NP is limited 
due to nanoparticles aggregation, low stability, the release 
of metal ions from media and indirect/direct toxicity [15]. 
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One way to overcome these problems is to immobilize the 
nanoparticles on the porous material such as silica, zeolite, 
etc. [16, 17]. Moreover, the decrease of silver leaching to 
a lower level than the health and environmental standards 
without a change in antibacterial properties and maintaining 
them in the long term is an important task [18, 19].
One of the candidate compounds for metal immobiliz-
ing is metal–organic frameworks (MOFs). These porous 
coordination polymers made up of various organic bridg-
ing ligands and metal ions and have large surface areas and 
high porosity [20–22]. MOFs are one of the most important 
porous materials that have been used extensively in many 
cases such as separation [23], heterogeneous catalysis [24], 
sensing [25, 26] and drug release [27], adsorption [28–30] 
and air purification [31, 32].
The antibacterial activities of MOFs have been reported 
in several studies [33–37]. MIL-101(Cr) is a MOF which has 
large cavities (more than 30 Å) with coordinatively unsatu-
rated sites (CUSs). There are suitable properties such as high 
thermal, chemical, and solvent stability in MIL-101(Cr) for 
connecting to functionalized groups [38–41]. Post-synthesis 
modification of MOFs by incorporation of metal ions and 
organic molecules is a suitable approach to improve MOFs 
properties [38, 42–45].
N-alkylated imidazole appears to promise a potential to 
use as an antibacterial and antifungal agent [46–48]. On the 
other hand, embedding imidazole into the pore spaces of 
MOFs increases the concentration of protons [49–52]. The 
positive surface charge of antibacterial materials is impor-
tant for bacterial adhesion [53]. The positively charged 
grafted onto the MIL-101(Cr) surface by imidazole confers 
electrostatic attraction between imidazole functionalized 
MIL-101(Cr) and negatively charged surface of bacteria 
[54, 55].
Research motivation in this study was to understand the 
synergistic effect between silver NPs and imidazole as a 
bactericidal. In this context, antibacterial activities of MIL-
101(Cr), Ag/MIL-101(Cr), and MIL-101(Cr)/IMI have been 
investigated and results compared with antibacterial activity 
of Ag/MIL-101(Cr)/IMI.
2  Materials and methods
2.1  Chemicals and materials
All solvents and reactants, including chromium(III) 
nitrate nonahydrate (Cr(NO3)3·9H2O, 99%), tereph-
thalic acid  (C6H4(COOH)2, 98%), silver nitrate  (AgNO3, 
99%), sodium borohydride  (NaBH4, 96%), ethanol 
 (C2H5OH, pure), anhydrous toluene  (C6H5CH3, 99.8%), 
acetone  (CH3COCH3, pure), N,N-dimethylformamide 
((CH3)2CHO, 99.8%), imidazole  (C3H4N2, 99%) were 
commercially purchased from either Sigma-Aldrich or 
Merck Chemical and used without further purification. 
Both Mueller–Hinton broth and blood agar (TSA) were 
also procured from Merck.
2.2  Materials characterization
Powder X-ray diffraction (XRD) patterns were recorded 
on a STOE diffractometer with the operating power of 
40 kV/40 mA, and the diffraction data were collected 
between 5° and 80° (2θ) using the Cu Kα radiation 
(λ = 1.5418 Å). FE-SEM (TESCAN/MIRA3) and TEM 
(Philips CM30) operating at 200 kV were employed to 
determine the Ag/MIL-101(Cr)/IMI morphology and par-
ticle size. The size distribution of silver NPs were calcu-
lated using the Image software.
BET surface area measurements were conducted using 
a BELSORP-mini II (BEL Japan) apparatus at liquid 
nitrogen temperature (77 K). The sample was degassed 
at 423 K for 3 h and surface areas were calculated using 
the BET equation between P/P0 = 0–0.05. The total pore 
volume was carried out by a single point method at P/
P0 = 0.984.
Ag content of Ag/MIL-101(Cr)/IMI and the leaching of 
Ag and Cr from post-synthesized MOF were analyzed by 
inductively coupled plasma optical emission spectrometry 
(Vista pro, Varian) and elemental analyses (for C/H/N) were 
determined using Elemental CHNS Analyzer Vario El III 
analyzer. Fourier transform infrared (FTIR) spectra (WQF-
510A) were obtained with KBr disks in 400–4000 cm−1. 
Thermal analysis (TG–DTA) was conducted on a Bahr STA-
503 instrument. The leaching of imidazole was determined 
by HPLC–MS (MODEL: Waters Alliance 2695 HPLC-
Micromass Quattro Micro API Mass Spectrometer).
2.3  Synthesis of MIL‑101(Cr) nanoparticles
MIL-101(Cr) was hydrothermally synthesized according to 
Bromberg et al. method [56]. Briefly, chromium (III) nitrate 
nonahydrate (10 g), terephthalic acid (4.15 g), and deionized 
water (100 mL) were mixed and put in a 500 mL Teflon-
lined autoclave. Then autoclave was heated at 218 °C for 
18 h without stirring. After cooling autoclave to ambient 
temperature, the suspension was centrifuged to separate 
the green solid of MIL-101(Cr) from the water. This sedi-
ment was washed with water, methanol and acetone. Pow-
der of MIL-101(Cr) was placed in N,N-dimethylformamide 
(100 mL) and was sonicated for 10 min and then kept over-
night at 70 °C. The product was washed with methanol and 
acetone. Finally, it was activated at 150 °C under vacuum 
for 12 h.
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2.4  Synthesis of Ag/MIL‑101(Cr)/IMI
Scheme 1 shows the strategy for the preparation of imida-
zole-functionalized Ag/MIL-101(Cr), which adapted from 
Cao et al. report [57]. Briefly, activated MIL-101(Cr) (1.0 g) 
was immersed in deionized water (40 mL) containing silver 
nitrate (250 mg) and was stirred for 14 h at room tempera-
ture (25% w/w). Next, the suspension was dried under the 
vacuum for 2 h at 100 °C. Finally,  Ag+ was reduced to  Ag0 
by 4 mL of 1.7 mmol/mL  NaBH4 (250 mg), while it was 
agitated at room temperature for 1 h.
For the preparation of imidazole-functionalized MOF 
(MIL-101(Cr)/IMI), 1.0 g of activated MIL-101(Cr) was 
suspended in 100 mL of anhydrous toluene and then imida-
zole (100 mg) was dissolved in anhydrous toluene (10 mL) 
and added to the slurry dropwise. This blend was refluxed at 
120 °C for 15 h with continuous stirring [38]. The product 
was centrifuged and then washed with ethanol and deionized 
water. Finally, the product was dried in a vacuum oven at 
80 °C for 4 h to yield MIL-101(Cr)/IMI. Ag/MIL-101(Cr)/
IMI was prepared similarly using Ag/MIL-101(Cr).
2.5  Antibacterial activity tests
Antibacterial activity tests of the Ag/MIL-101(Cr), MIL-
101(Cr)/IMI and Ag/MIL-101(Cr)/IMI were performed 
Scheme. 1  Synthesis of Ag/MIL-101(Cr)/IMI antibacterial agent from MIL-101(Cr), imidazole and silver NP
 Journal of Porous Materials
1 3
against the Gram-positive Staphylococcus aureus ATCC 
25923 (S. aureus) and Gram-negative Escherichia coli ATCC 
25922 (E. coli). Reference strains were purchased from 
Padtanteb Co. in Iran. Strains of E. coli and S. aureus were 
inoculated into Mueller–Hinton broth to culture the bacteria 
at 37 °C for 20 h. Moreover, fresh bacteria were incubated 
on the blood agar plates at 37 °C for 20 h. Minimum inhibi-
tory concentration (MIC) and minimum bactericidal concen-
tration (MBC) levels of post-synthesized MIL-101(Cr) were 
evaluated according to CLSI recommendations [58]. Briefly, 
stock concentrations of 320 mg/mL from the compounds were 
prepared in sterile distilled water and 0.5% dimethylsulfoxide 
(DMSO). The concentrations of the working solutions were 
selected around 16 dilutions between 80 mg/mL and 2.25 μg/
mL. The colonies were touched with a loop; the loop was then 
suspended in 0.9% saline solution, and the turbidity of the bac-
terial suspension was adjusted to 0.5 McFarland standard. The 
suspension was subsequently diluted 1 in 50 where the con-
centration of bacteria was nearly  106 CFU/mL. Sterile Muel-
ler–Hinton broth (100 μL) was added to all wells of a 96-well 
plates; 100 μL of synthesized agents were then added to the 
two rows of each plate, and 1:2 serial dilutions were prepared 
in each column of wells. The final concentration was between 
1 × 105 and 1 × 106 CFU/mL in the 96-well plates. Then, the 
microplates were placed in an incubator at 37 °C for 20 h. Gen-
tamicin (10 mg/mL) was used as a positive control, for each 
bacterial strain. A growth control (without synthesized agents) 
and a sterile control (without bacteria) were also included. To 
determine the MBC and MIC levels, 15 μL aliquots were taken 
from the wells; were plated on Mueller–Hinton agar plates and 
were then incubated for 24 h at 37 °C. The lowest concentra-
tion of chemicals that destroyed 99.9% of the initial bacteria 
was considered as MBC, while the MIC was determined as the 
lowest concentration of the agent which inhibited the growth 
of them. Each test was repeated in at least triplicate.
2.6  Silver and imidazole leaching from Ag/
MIL‑101(Cr)/IMI
First, 21  mg of Ag/MIL-101(Cr)/IMI was poured into 
100 mL of distilled water. Next, the prepared sample was 
stirred for 24 h at 120 rpm using a magnetic mixer. Finally, 
5 mL of supernatant was analyzed by ICP-OES for Ag and 
chromium and HPLC–MS for imidazole leaching.
3  Results and discussion
3.1  Characteristics of nanoparticles
Powder X-ray diffraction patterns of MIL-101(Cr), Ag/MIL-
101(Cr) and Ag/MIL-101(Cr)/IMI are shown in Fig. 1. As 
can be seen, the XRD patterns of Ag/MIL-10(Cr) and Ag/
IMI/MIL-10(Cr) are consistent with the XRD pattern of 
MIL-101(Cr) which indicate the framework structure of 
MIL-101(Cr) after doping with silver and also after treat-
ing of post-synthesized Ag/MIL-101(Cr) with imidazole 
has been preserved. Further, the appearance of well-shaped 
diffractions at 2Ѳ of 38°, 44°, 64°, and 77° demonstrate the 
presence of silver NPs in MIL-101(Cr) [59, 60]. Also, FTIR 
spectrum of MIL-101(Cr) in the range of 1600–500 cm−1 
(Fig. 1S) with well define stretching vibration band of Cr–O 
at 570 cm−1 confirm that the structure of MIL-101(Cr) 
remained intact after loading silver and treating with imida-
zole [61]. Furthermore, the bands at 2925 and 1051 cm−1 in 
FT-IR spectrum of Ag/MIL-101(Cr)/IMI have been assigned 
to the aliphatic C–H, and C–N stretching vibrations, respec-
tively [38, 39], and unambiguously indicate the presence of 
imidazole in target compound.
Figures 2 and 3 shows the FESEM and TEM images of 
the Ag/MIL-101(Cr)/IMI nanocrystal. The particle size of 
Ag/MIL-101(Cr)/IMI was in the range from 150 to 253 nm. 
The mean diameter of Ag nanoparticles from TEM image 
was determined to be 11.34 ± 3.85 nm (Fig. 3). Interest-
ingly, there is a uniform distribution of the selected particles 
length in EDS mapping and line scan of Ag/MIL-101(Cr)/
IMI where Ag is located in the internal core structure along 
with C, O, Cr elements and imidazole (N) is placed in the 
external shell (Figs. 2S and 4). Moreover, N and Ag signals 
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Fig. 1  X-Ray diffraction patterns of MIL-101(Cr), Ag/MIL-101(Cr) 
and Ag/MIL-101(Cr)/IMI
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at 0.3 and 2.5 keV confirm the existence of N and Ag ele-
ments in Ag/MIL-101(Cr)/IMI crystal [16, 62].
Nitrogen adsorption–desorption isotherms exhibit that 
surface area and total pore volumes of Ag/MIL-101(Cr)/
IMI have declined compared to those of MIL-101 (Cr). 
BET surface area of nanocrystal decreased from 1835 to 
426 m2/g (Fig. 5) and total pore volumes declined from 
0.87 to 0.258 cm3/g [63]. Therefore, it was concluded that 
the pores of MIL-101(Cr) were not significantly closed 
after silver doping and imidazole-functionalizing, while 
significant reduction has been reported in the surface area 
and the pore volume of amine-functionalized zeolite NaY 
[54]. Thermal analysis was conducted to study the stability 
of the Ag/MIL-101(Cr)/IMI. As TG curve in Fig. 6 shows, 
there is about 40% mass loss from 350–550°C. This mass 
loss is accompanied by exothermic peaks in the DTA curve 
in the same temperature and indicates a rapid decomposi-
tion of the Ag/MIL-101(Cr)/IMI, therefore, it can be con-
cluded that the prepared nanoparticles thermally are stable 
up to 380 °C.
Table 1 lists the amount of doped silver and imida-
zole in different MIL-101(Cr) post-synthetized com-
pounds. The level of Ag-doped in Ag/MIL-101(Cr)/IMI 
nanoparticles assessed to be 8.1% according to ICP-OES 
analysis. To determine the amount of imidazole in Ag/
MIL-101(Cr)/IMI, its nitrogen content was determined by 
CHNS Elemental Analyzer. The amount of nitrogen was 
5.96 wt%. Therefore, it can be concluded that imidazole 
loading was 14.49 wt% in combination with C, 31.49%; 
H, 2.7% and C/N ratio, 5.28.
Fig. 2  FE-SEM image of Ag/
MIL-101(Cr)/IMI
Fig. 3  TEM images of Ag/
MIL-101(Cr)/IMI and the size 
distribution of Silver NPs
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3.2  Leaching of silver and imidazole
The amount of Ag leaching in distilled water was meas-
ured to be 0.714 mg from 1.0 g of Ag/MIL-101(Cr)/IMI, 
while 81 mg of Ag has been doped to 1.0 g of post-syn-
thesized MOF. The percentage of silver leaching from 
Ag/MIL-101(Cr)/IMI (0.88%) is lower than the reported 
leaching of similar studies [18, 54, 64]. The silver leach-
ing rate in this study was 150 µg/L, while a leaching limit 
of 100 µg/L has been recommended by the World Health 
Fig. 4  Line-scan EDX in an area; (a) (carbon), (b) (chrome), (c) (oxygen), (d) (silver), (e) (nitrogen)
Fig. 5  N2 adsorption–desorption isotherms at 77 K for MIL-101(Cr), 
Ag/MIL-101(Cr)/IMI
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Fig. 6  TG-DTA profile of Ag/MIL-101(Cr)/IMI
Table 1  Percent of doped agents in different MIL-101(Cr) post syn-
thetized compound
Compound Ag Imidazole
Ag/MIL-101(Cr) 13.7 –
MIL-101(Cr)/IMI – 15.55
Ag/MIL-101(Cr)/IMI 8.1 14.49
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Organization (WHO) in bacteriostatic agents [65]. The level 
of 144.9 mg of imidazole was assessed in 1.0 g of Ag/MIL-
101(Cr)/IMI, while 3.94 mg (2.72%) was leached for each 
1.0 g of Ag/MIL-101(Cr)/IMI. According to the Registry 
of Toxic Effects of Chemical Substances (RTECS) from 
NIOSH, DNA inhibition in humans by imidazole occurs 
in 68 mg/L, while imidazole leaching was 0.828 mg/L in 
this study [66]. It seems that the leaching of imidazole from 
Ag/MIL-101(Cr)/IMI is lower than the limit level of health. 
The chromium leaching rate was measured to be 153 µg/L 
for Ag/MIL-101(Cr)/IMI, while a limit of 50 and 100 µg/L 
have been recommended for drinking water by the WHO and 
the U.S.EPA, respectively [67, 68]. Based on the EDS map-
ping, elemental Ag and imidazole locate in the internal core 
and external shell, respectively, which affect the reduction 
of leaching process. However, imidazole can be substituted 
with water (or OH) molecules providing the coordinately 
unsaturated sites (CUSs) of Ag/MIL-101(Cr). Consequently, 
this produces the strong interactions between imidazole and 
Ag/MIL-101(Cr) which leads to minimizing the leaching of 
imidazole [40]. Since the XRD pattern of Ag/MIL-101(Cr) 
after introducing imidazole did not change therefore, it can 
be concluded that Ag and imidazole interaction did not take 
place. Such a low silver leaching can be attributed to the low 
solubility of elemental silver in aqueous solution.
3.3  Antibacterial activity
The main aim of this study was to prepare a suitable antibac-
terial nanoparticle with good antibacterial activity and low 
leaching rate. To achieve this goal, imidazole and silver with 
antibacterial properties [13, 46] were selected. In the other 
hand, the surface area and the pores in the MIL-101 are large 
enough to embed imidazole and silver NP [69]. Therefore, 
Ag/MIL-101(Cr)/IMI was synthesized and its antibacterial 
activity was evaluated by the MIC/MBC techniques against 
E. coli and S. aureus bacteria.
Inhibition strengths of different nanoparticles are shown 
in Fig. 3S. The results of Table 2 shows that the MIC of 
MIL-101(Cr) is 20 mg/mL for E. coli in MIL-101(Cr). In a 
similar report, MIC result of Commercial Cu-BTC has been 
64 mg/mL for E. coli [70]. The MIC of E. coli decreased 
from 20 to 0.3 mg/mL in Ag/MIL-101(Cr).
The results of Table 2 suggest that, in addition to reducing 
the values of MIC/MBC by silver NP, imidazole-functional-
ized also enhances the antibacterial activity of MIL-101(Cr). 
The remarkable point is that silver NP and imidazole have a 
synergistic effect, which has been presented in the antibacte-
rial potency of Ag/MIL-101(Cr)/IMI.
It should be noted that the reduction of the silver ion 
 (Ag+) to the elemental Ag in zeolite decreases the anti-
bacterial activity [71]. The antimicrobial activity of Ag/
MIL-101(Cr)/IMI (MIC; 0.076 mg/mL, 8.1 wt% Ag) is 
comparable with that of  Ag+/zeolite (MIC; 0.2 to 0.5 mg/
mL, 9.8 wt% Ag) reported by Ferreira et  al. [72, 73] 
despite the reduction of the silver. Consequently,  Ag+ is 
released slower than  Ag+ led to an increase in the bac-
tericidal activity of Ag/MIL-101(Cr)/IMI in the long 
term [18]. Therefore, it can be concluded that the anti-
bacterial activity of Ag/MIL-101(Cr)/IMI is preferred to 
ion-exchanged zeolite due to higher host potency as well 
as lower leaching efficacy. Silver NPs based MOFs by 
Lu et al. were demonstrated to have antibacterial activ-
ity with MIC of 5–15 μg/mL and leaching of Ag was 
18.76–25.1 ppm while leaching rate of silver was 0.15 ppm 
in this work [74].
Mortada et al. prepared postmetalated MOFs and tested 
it against E. coli. MIC of UiO-67-bpdc-Ag was 50 μg/mL 
which is equivalent to 6.5 μg/mL of silver content with 
0.85% of the silver leached [75]. The MIC of 6.2 μg/mL of 
silver content with 0.88% of the silver leaching reported in 
this research. It is necessary to mention, the mass ratio of the 
MOF/AgNO3 in the synthesis of UiO-67-bpdc-Ag was 1:2 
[75], but in this work, the mass ratio for the synthesis of Ag/
MIL-101(Cr)/IMI is 1:4 which indicated less  AgNO3 con-
sumption. Erchel et al. investigated the antibacterial activity 
of Ag3(3-phosphonobenzoate) for E. coli with a reported 
MIC of 50 μM and leaching of at least 1.2% [76].
Imidazole-functionalized not only has intrinsic antibacte-
rial activity but also increases the protons conductivity of 
Ag/MIL-101(Cr) [51, 52]. This potency could increase the 
antibacterial activity due to electrostatic attraction between 
the positively charged surface of the Ag/MIL-101(Cr) and 
negatively charged membranes of bacteria, which lead to 
adhesion of bacteria to the supporter surface [53]. As stated 
in various reports [55, 77], biocidal mechanisms of nano-
particles can be summarized as follows: (1) Adhering of the 
bacterial cell membrane to the surface of media; (2) Pen-
etrating inside the cells and disruption in the intracellular 
organizations; (3) Free radicals and reactive oxygen species 
(ROS) generation. The TEM results of Ag/MIL-101(Cr)/IMI 
show that the mean diameter of silver NPs were 11.34 nm. 
Therefore, it can be concluded that a smaller silver NP enters 
the bacteria directly and can boost the generation of free 
Table 2  Minimal inhibitory concentration (MIC) and minimal bacte-
ricidal concentration (MBC) results in mg mL−1 of antibacterial agent
E. coli S. aureus
MIC MBC MIC MBC
MIL-101(Cr) 40 80 80 160
MIL-101(Cr)/IMI 20 40 40 80
Ag/MIL-101(Cr) 0.306 0.612 0.612 1.225
Ag/MIL-101(Cr)/IMI 0.076 0.153 0.306 0.612
Gentamicin 0.0005 0.001 0.009 0.018
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radicals, causing stronger antimicrobial activity according 
to previous studies [78, 79].
The results of this study show that S. aureus is less 
susceptible to Ag/MIL-101(Cr)/IMI than E. coli bacteria. 
It could be related to the thickness of the cell membrane, 
whereas the peptidoglycan layer of  G+ bacteria is thicker 
than  G− types. Many similar studies confirm the findings of 
the present research [80, 81].
4  Conclusion
Overall, in this work, Ag/MIL-101(Cr)/IMI was first syn-
thesized as a proper nanoparticle for antibacterial applica-
tions. The post-synthesis of MIL-101(Cr) with imidazole 
and silver NP led to an outstanding synergistic effect of 
antibacterial activity towards different pathogens including 
E. coli and S. aureus. Ag/MIL-101(Cr)/IMI showed much 
better MIC/MBC values than Ag/MIL-101(Cr). Also, this 
study presented that in spite of the limited leaching of silver 
and imidazole from Ag/MIL-101(Cr)/IMI, the antibacterial 
activity is at a desirable level. The leaching levels of silver 
NP and chromium is tended to be around the standard of 
WHO and EPA, while the leaching level of imidazole was 
lower than the level recommended by RTECS from NIOSH 
organization.
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